4061 Stock Overview
Denka Company Limited manufactures and sells organic and inorganic materials to electronic materials and pharmaceuticals in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Denka Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2,266.50 |
| 52 Week High | JP¥2,909.00 |
| 52 Week Low | JP¥2,202.50 |
| Beta | 0.50 |
| 1 Month Change | -7.02% |
| 3 Month Change | -11.90% |
| 1 Year Change | -15.24% |
| 3 Year Change | -46.36% |
| 5 Year Change | -32.14% |
| Change since IPO | 2.09% |
Recent News & Updates
Shareholder Returns
| 4061 | JP Chemicals | JP Market | |
|---|---|---|---|
| 7D | 2.1% | -1.2% | -1.0% |
| 1Y | -15.2% | 27.3% | 27.9% |
Return vs Industry: 4061 underperformed the JP Chemicals industry which returned 27.3% over the past year.
Return vs Market: 4061 underperformed the JP Market which returned 27.9% over the past year.
Price Volatility
| 4061 volatility | |
|---|---|
| 4061 Average Weekly Movement | 2.9% |
| Chemicals Industry Average Movement | 3.7% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4061 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4061's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1915 | 6,406 | Toshio Imai | www.denka.co.jp |
Denka Company Limited manufactures and sells organic and inorganic materials to electronic materials and pharmaceuticals in Japan and internationally. The company’s Electronics & Innovative Products division provides conductive agents for lithium for lithium-ion batteries, thermal materials and substrates, functional ceramics, films, and tapes. Its Life Innovation division works to improve people's life in the fields of prevention, diagnosis, and treatment, including influenza vaccines; test reagents, such as rapid testing kits for COVID-19; and macromolecular hyaluronate preparations.
Denka Company Limited Fundamentals Summary
| 4061 fundamental statistics | |
|---|---|
| Market cap | JP¥195.32b |
| Earnings (TTM) | JP¥7.51b |
| Revenue (TTM) | JP¥391.67b |
26.0x
P/E Ratio0.5x
P/S RatioIs 4061 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4061 income statement (TTM) | |
|---|---|
| Revenue | JP¥391.67b |
| Cost of Revenue | JP¥305.37b |
| Gross Profit | JP¥86.30b |
| Other Expenses | JP¥78.79b |
| Earnings | JP¥7.51b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 10, 2024
| Earnings per share (EPS) | 87.12 |
| Gross Margin | 22.03% |
| Net Profit Margin | 1.92% |
| Debt/Equity Ratio | 64.9% |
How did 4061 perform over the long term?
See historical performance and comparison